In this blog Margot Puerta reports on the Bioelectronic Medicine: Technology Targeting Molecular Mechanisms symposium which took place in June. This three-day meeting had the aim of developing the field of bioelectronic medicine and brought together leading scientists and industry leaders from around the globe.
Technology is changing the world, including the world of pharmacological therapies that target molecular mechanisms. These therapies are expensive, difficult to administer, often toxic, and may be accompanied by lethal side effects. Through a convergence of molecular medicine, neuroscience and bioengineering, bioelectronic medicine seeks to develop cures that don’t require drugs or rely on them less heavily.
The second symposium, Bioelectronic Medicine: Technology Targeting Molecular Mechanisms was held June 12–14 in Saltsjöbaden, Sweden, presented by the Feinstein Institute for Medical Research, the Karolinska Institutet, and the Journal of Internal Medicine.
The field of bioelectronic medicine is aimed at interfacing electronics with nerves to specifically target the biological processes underlying disease. Bioelectronic medicine is now at a crossroads of the future of medical research where healthcare, technology and science join.
“With the discoveries that have been announced, and the research collaborations that are spanning the globe, the pace of bioelectronic medicine is accelerating,” said Kevin J. Tracey, MD, president and CEO of the Feinstein Institute and Editor in Chief of Bioelectronic Medicine. “As the global scientific home of bioelectronic medicine, it is important that the Feinstein Institute host a forum to discuss new findings and drive new discovery. We achieved that goal with this latest symposium.”
The three-day meeting brought together leading scientists and global experts from major institutions as well as industry leaders in biotechnology, including Galvani Bioelectronics, General Electric, GlaxoSmithKline, Medtronic and SetPoint Medical. The goal was to explore, define, and further develop the field of bioelectronic medicine. Session topics included: Defining Circuits, Clinical Updates, Molecular Targets, Neural Interfaces, Signal Processing, Disruptive Tools and Technology, and Accelerating Clinical Translation.
Presenters were encouraged to show their most recent advances. Many of the presentations included unpublished data, sparking thought-provoking discussion while contributing excitement about the latest developments in the field. At least one presenter was interrupted by spontaneous applause midway through the presentation. “I am inspired by the science, by the field advances, and by our collaborations in the short time since our groups hosted the last meeting in 2016,” said Peder Olofsson, MD, PhD, director of the Center for Bioelectronic Medicine at the Karolinska Institutet, and a chair of the symposia.
Read more at http://bit.ly/2KJTlu9